Proxiomics lands $49,000 Venture Kick grant to automate lab data checks
What's the deal? Swiss startup ProxiomicsDealroom has a profile for this one. Try Dealroom → has received a US$36.7K grant from Venture KickDealroom has a profile for this one. Try Dealroom → to develop its AI-powered platform for mass spectrometry data analysis. The software combines data from different instrument brands into one workflow and uses its StudyGuard technology to detect errors, automate settings, and make results traceable.
Why now? The company is moving from a research tool to a commercial product. During the Venture Kick program, it found its first customers and began integrating the platform into their daily workflows.
What's the endgame? The grant will mainly fund computing infrastructure, data storage, and two part-time machine learning engineers to build and test the first StudyGuard models. Proxiomics also plans to invest in customer visits, pilot onboarding, marketing, and preparations for a seed round.
What's the product? Proxiomics says laboratory leaders are overwhelmed by fragmented workflows spanning experiment design, instrument maintenance, data analysis, and reporting. In some cases, it says, those inefficiencies cost companies hundreds of thousands in lost revenue. The platform aims to cut manual work and generate reliable, fully traceable results.
How it fits: Mass-spectrometry software is drawing growing interest as labs seek to automate processing and improve consistency. Recent moves include WatersDealroom has a profile for this one. Try Dealroom →' AI-enabled LC-MS workflow initiative and mzioDealroom has a profile for this one. Try Dealroom →'s automation layer for mass-spectrometry processing. Proxiomics targets a narrower niche: quality control, a prerequisite for scalable analysis.
What could go wrong? The award's significance will depend on whether Proxiomics can show its product works across instruments and fits existing lab workflows.
The signal: At roughly $49,000, this is a modest early-stage grant — it ranks in just the 14th percentile by amount — not a major financing event. But it supports a timely problem, and the company now says it sees room to scale faster alongside the expanding life sciences market rather than simply reaching break-even.
Read more: venturekick.ch
Image credit: Generated with Gemini
